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Highlights
• This review highlights state-of-the-art technologies in cell and molecular biology. The directions 
of cardiovascular disease research where these technologies may lead to breakthrough discoveries are 
discussed.
Abstract
Heart and vascular diseases are responsible for tens of millions of deaths 
annually, underscoring an urgent need to improve the existing clinical practice 
in order to benefit patients. Advancement of basic science and technology 
enables understanding of disease etiology and pathogenesis at a deeper level of 
complexity. This mini-review article provides a summary of recent methods of cell 
and molecular biology applicable for current cardiovascular research. Widespread 
application of these approaches in cardiovascular disease research will be a key 
factor in the prolonged longevity and life expectancy of the general population.
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Introduction
Cardiovascular disease (CVD) is the leading cause 
of mortality and invalidization in the world.  Russia 
is a country with one of the highest CVD deaths 
worldwide. In 2019, Russia showed the world's highest 
disability-adjusted life-years due to peripheral artery 
disease, alcoholic cardiomyopathy, cardiomyopathy 
and myocarditis, and high low-density lipoprotein 
(LDL) cholesterol [1]. This ominous statistic could 
be explained by a combination of factors including 
social, economic, geographical, etc. On the bright 
side, however, the age-standardized CVD death rates 
in Russia have reduced by more than 20% in the last 
10 years, largely due to improvements in hospital 
infrastructure allowing better access to healthcare for 
patients in dire need. 
Even though the pathophysiology of CVD is 
generally well studied, while CVD risk factors 
are modifiable and can be controlled with altered 
behavior, more basic cardiovascular research is 
needed to improve current CVD treatment modalities 
and develop targeted therapies tailored to a patient's 
requirements. Twenty years ago, a protein serine 
protease proprotein convertase subtilisin/kexin type 
9 was found to bind LDL receptor (LDLR), which 
induced a conformational change in the LDLR, marking 
it for lysosomal degradation, which eventually led to 
a reduced LDL-cholesterol in the blood serum [2, 3].
This fundamental discovery made in a laboratory 
opened a possibility of lipid-lowering therapy for 
patients with statin intolerance or those with familial 
hypercholesterolemia, therefore offering a therapeutic 
niche for selective high-risk patients.
The last decade has seen a major technological 
development leading to the emergence of novel methods 
of cell and molecular biology. These new approaches 
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allow a deeper understanding of the occurrence and 
progression of diseases at unprecedented resolution. 
In this review article, I summarize the state-of-the-art 
technology applicable to current basic cardiovascular 
research.
Imaging Mass Cytometry 
Immunostaining has been a major discovery tool 
for decades. This technique dates back to 1941 when 
Coons and colleagues developed immunofluorescence 
techniques for labeling antibodies [4]. While classical 
immunostaining is effective for both qualitative and 
quantitative analysis of several proteins of interest 
on one slide (usually 1 to 4), it does not allow the 
simultaneous staining of multiple (10+) antigens on the 
same slide. This is a major limitation in the era of big 
data and high-throughput technologies, and therefore 
immunohistochemistry and immunofluorescence 
(collectively termed immunostaining) are suboptimal 
options for use in precious clinical specimens such 
as tissue microarrays. In addition, conventional 
immunohistochemistry techniques have a number of 
other limitations concisely summarized by Rimm [5].
Imaging mass-cytometry (IMC) is a very recent 
method [6] enabling simultaneous interrogation of 
multiple protein markers (up to 37) on a single glass 
slide. Fluorescence spectra used in immunofluorescence 
staining have relatively broad peaks that could lead to 
significant signal overlaps (Figure 1A). On the contrary, 
the IMC technology uses metal tag spectra that are 
based on mass and are detected as discrete peaks of 
similar intensity for similar protein expression levels 
(Figure 1B). Once antibodies of interest are conjugated 
to metal tags (usually lanthanides), they can be mixed 
together and applied onto a tissue in a way similar to 
the classical immunostaining protocol, followed by a 
signal detection using a high-resolution laser ablation 
system coupled to a mass cytometer (Figure 1C). As 
a result, dozens of antigens can be simultaneously 
evaluated on a single slide. Since rare-earth-metal 
isotopes used as tags do not normally occur in vivo, 
IMC images produce almost no background noise; 
therefore, the contrast between antigens of interest and 
the background is perfect for image analysis.
So far, IMC application in cardiovascular research 
has been very limited; nonetheless, it was used to address 
highly relevant scientific questions. In particular, IMC 
was used to identify new diagnostic targets of acute 
cardiac infarction [7], characterize stenotic aortic 
valve tissues [8], and analyze the metabolic flow in an 
ischemic heart [9]. These studies are all observational in 
nature, and it would be desirable to further apply IMC 
for dissecting signaling networks behind poorly studied 
CVDs such as, for example, Takotsubo syndrome 
(TTS). It remains unclear how emotional stress leads 
to myocardial toxicity in TTS. In some patients, TTS 
may lead to serious complications or even death [10]. 
To gain a deeper understanding of TTS at a molecular 
level, the in-depth IMC investigation of TTS-affected 
left ventricles would be a feasible approach. Another
Figure 1. General principle of imaging mass cytometry. A. Typical emission spectra produced by fluorophores commonly 
used for immunostaining. Each peak corresponds to a fluorophore. Note a significant amount of overlap between the 
adjacent fluorophores’ spectra. B. Isotopic mass spectra of metal tags used for imaging mass cytometry. Because each tag’s 
molecular mass has a discrete value (rather than range), there is no overlap between dozens of tags used simultaneously. 
C. Schematic illustrating the principle of  imaging mass cytometry and the list of 39 lanthanide metal tags commonly used 
for imaging mass cytometry. Created with BioRender.com (BioRender's Academic License). 








example is Tetralogy of Fallot (TOF), a congenital 
heart defect with an unknown cause, characterized by 
right ventricular hypertrophy, ventricular septal defect, 
pulmonary stenosis, and overriding aorta [11]. Even 
though TOF can be treated surgically with a high rate 
of success, understanding molecular mechanisms of 
this disease at a cell level using IMC would greatly 
expand our knowledge about cardiovascular disorders.
Ribosome profiling
The emergence of ribonucleic acid (RNA) 
sequencing (RNA-seq) has revolutionized biomedical 
research [12]. This high-throughput method allows for 
counting of RNA molecules in a sample by quantifying 
the sequenced fragments per kilobase of the exon 
model per million mapped reads.  RNA-seq quickly 
became a method of choice for those interested in 
understanding how particular conditions or treatments 
influence cells both in vitro and in vivo. Unfortunately, 
messenger ribonucleic acid (mRNA) concentrations do 
not always directly correlate with the concentration of 
a corresponding protein in a sample [13]. This could be 
due to multiple reasons, including that large amounts 
of mRNA are targeted for degradation and therefore 
never translated [14]. 
A more advanced RNA-seq method of ribosome 
profiling (Ribo-seq) represents a tool allowing to 
exclusively measure mRNA that is being translated 
at the moment [15]. The principle of Ribo-seq is 
the immobilization of ribosome-mRNA complexes 
followed by their isolation from cells. At the first step, 
cultured cells are pre-incubated with drugs binding 
to the ribosome E-site, thus blocking elongating 
ribosomes in their pre-translocation step. Ribosomes in 
the post-initiation stage can also be blocked if needed. 
Cells are further lysed in the presence of RNase I that 
digests all RNA outside the ribosome-mRNA complex 
(ribosomes protect mRNA from RNase I digestion). At 
the final step, ribosome-specific ribosomal ribonucleic 
acid (rRNA) is depleted and resultant mRNA fragments 
are converted into a deoxyribonucleic acid (DNA) 
library suitable for deep sequencing by a standard 
RNA-seq analysis protocol [16]. 
Ribo-seq provides an opportunity to analyze 
biologically meaningful transcriptomes highly relevant 
to a given experimental condition. In comparison with 
classical RNA-seq, the use of Ribo-seq may enable 
more accurate and reproducible results with less 
noise signals generally associated with irrelevant, 
non-translated transcripts. Cardiovascular research 
will greatly benefit from the widespread application 
of Ribo-seq technology, especially in settings where 
dynamic transcriptome changes in a short time 
period are important to gain new knowledge. For 
example, in vitro studies under flow conditions are 
considered a gold standard in the area of endothelial 
cell biology research [17–19]. However, the phenotype 
of endothelial cultured under flow is highly unstable 
owing to sensitivity to a multitude of factors such 
as time spent in the flow system, flow rate, cell 
confluency, etc. (Kutikhin, personal communications). 
Thus, studies under flow supplemented by Ribo-seq 
translatome analysis may allow the generation of more 
trustworthy and reproducible in vitro results.
Single-cell RNA sequencing
Due to the stochastic nature of biological processes, 
there is substantial cell-to-cell variability in the 
transcriptome of multicellular organisms [20]. Recent 
advances in microfluidics and nanotechnology have 
led to the boom in various single-cell sequencing 
techniques, including single-cell RNA sequencing 
(scRNA-seq). Profiling the transcriptome at a single-
cell resolution has a number of advantages over classic 
approaches such as microarray or “bulk” RNA-seq. 
First, scRNA-seq reveals the diversity of phenotypes 
and cell states, which could provide novel insights 
about disease etiology or pathogenesis. Second, owing 
to the deconvolution of heterogeneous cell populations, 
scRNA-seq enables the identification of rare cell 
lineages within the tissue or organ of interest [21]. 
Third, multiple cell lineages derived from a single 
scRNA-seq experiment can be used to construct 
a trajectory inference (also called pseudotime), a 
quantitative measure describing how these distinct 
populations interact with each other in time [22]. 
Isolation of single cells for scRNA-seq can be 
achieved in a number of ways, including limiting 
dilution, micromanipulation, flow cytometry-activated 
cell sorting, microfluidic technology, negative magnetic 
separation, etc. These isolation methods have their 
own pros and cons; however, the comparison of these 
approaches is beyond the scope of this mini-review. 
Once live single cells are isolated, individual cells 
are lysed followed by the selection of polyadenylated 
mRNA molecules (e.g. mRNA) using poly[T]-primers. 
Thus, other RNA such as rRNA do not further proceed 
for sequencing. At the next step, RNA is reverse-
transcribed into complementary DNA followed by 
its amplification by polymerase chain reaction. The 
resultant samples can be directly submitted for library 
preparation and can be further subjected to deep 
sequencing in accordance with standard RNA-seq 
protocols. During the data analysis step, single cells 
can be clustered into cell types and states, based on 
their unique gene expression signature. In addition, 
cells can be ordered along a predicted trajectory in 
pseudotime, based on computational reconstruction 
analysis (Figure 2). The limitation of scRNA-seq is 
its extremely high cost, even though it has dropped 
significantly in the last couple of years. 
Similar to cytometry by time of flight, scRNA-
seq can be used for in-depth analysis of different 
cell populations in a tissue. This approach could be
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particularly useful to study atherosclerotic plaques 
that consist of multiple cell types, including 
endothelial cells, smooth muscle cells, infiltrating 
immune cells, etc. The advantage of scRNA-seq over 
cytometry by time of flight is that mRNA expression 
of each cell subpopulation can be studied in great 
detail. Therefore, scRNA-seq allows to study cell 
composition and additionally mRNA expression of 
each cell type. This method has proven immensely 
useful for a deep understanding of how the human 
body works both in norm and pathology; in 
particular, scRNAseq data is actively used to generate 
cardiovascular cell atlases [23]. 
Clustered regularly interspaced short 
palindromic repeats (CRISPR) functional screens
CRISPR-associated protein 9 (CRISPR-Cas9) is 
a gene editing technology established by 2020 Nobel 
Prize winners Emmanuelle Charpentier and Jennifer 
Doudna. The mechanism underlying CRISPR-Cas9 is 
a prokaryote defense system against viruses, whereby 
bacteria store viruses’ DNA fragments in their genome 
in order to recognize and target these viruses during 
subsequent infections. During their lifespan, bacteria 
that survive viral infections integrate new spacers into 
their DNA [24]. These spacers contain DNA sequences 
identical to certain parts of the viral genome. If the 
virus happens to attack the bacteria again, the latter 
transcribes the aforementioned spacer sequence 
(precursor CRISPR RNA) that further undergoes 
maturation, eventually generating individual CRISPR 
RNA (crRNAs), each composed of a repeat portion 
and a virus-targeting spacer. The resultant crRNAs 
associate with effector complexes including Cas 
proteins, and crRNA guides the final complex to the 
virus DNA, where Cas endonucleases cut the invader’s 
nucleic acid. Adaptation of this bacterial “adaptive 
immune response” machinery to the needs of gene 
engineering has led to the possibility of complete 
deletion of the gene of interest, or even replacing a 
gene with a customized DNA sequence [25].
For the purpose of genome editing, the bacterial 
system is greatly simplified and only contains two 
components; guide RNA (gRNA) of interest and Cas9 
protein. Using the library of gRNAs, it is possible to 
knock out hundreds or thousands of genes in a single 
experiment in order to identify which genes have 
functional relevance in a particular in vitro or in vivo 
setting. In a typical experiment, a panel of gRNAs 
is delivered to a system in two ways: (i) positive 
screening, that is, selection of genes that accumulate 
in a population of cells due to survival advantage they 
confer; (ii) negative screening, which identifies genes 
or pathways that do not survive the selection by a drug 
or treatment and therefore critical for cell growth and 
survival. In principle, such CRISPR screens may be 
utilized to identify new molecular pathways associated 
with drug resistance and other settings. In cardiovascular 
research, CRISPR screening may be particularly useful 
for a better understanding of molecular mechanisms 
underlying early stages of atherosclerosis, specifically, 
the endothelial injury, which is a trigger of platelet 
aggregation and adhesion of leukocytes. Using in vitro 
models of endothelial injury, CRISPR screening may 
help identify genes or pathways involved in resistance to 
endothelial injury induced by turbulent blood flow [26] 
or calciprotein particles [27]. This, in turn, could lead to a 
better atherosclerosis prevention in the future, as subjects 
prone to endothelial injury or calciprotein particle 
formation may be subjected to tailored therapies such as 
potential ethylenediaminetetraacetic acid administration.
Figure 2. Single-cell RNA sequencing pipeline. Cartoon demonstrating a step-by-step protocol of single-cell RNA sequencing 
analysis of human atherosclerotic plaque excised from a diseased coronary artery. Adapted from “Single Cell Sequencing”, 
by BioRender, June 2020. Retrieved from https://app.biorender.com/biorender-templates/t-5f2350bba193ae00b486136b-
single-cell-sequencing. Copyright 2021 by BioRender (BioRender's Academic License).




















In a cell, physical compaction of DNA into 
nucleosomes is tightly regulated so that only certain 
regions of chromatin can be transcribed at a given 
moment; as such, only accessible parts of the chromatin 
are available to transcription factors, whereas closed 
chromatin cannot be transcribed due to tight packaging 
of nucleosomes. Therefore, by defining the epigenetic 
landscape of living cells, chromatin accessibility acts as a 
major regulator of cell behavior. Transposase-accessible 
chromatin with sequencing (ATAC-Seq) is a recently 
developed method for epigenetic profiling of open 
chromatin. In comparison with previously developed 
similar methods, ATAC-Seq offers a faster experiment 
with a lower number of cells needed for analysis.
The principle of ATAC-Seq is specific labeling of 
accessible chromatin by hyperactive Tn5 Transposase, 
an enzyme that integrates certain sequences called next 
generation sequencing adapters into open chromatin 
DNA, whereas closed chromatin remains untagged [28]. 
The resulting tagged DNA can be further amplified by 
polymerase chain reaction followed by next generation 
sequencing. Sample preparation for ATAC-Seq takes 
several hours; in contrast, other similar methods 
such as formaldehyde-assisted isolation of regulatory 
elements and sequencing of DNase I hypersensitive 
sites require 3–4 days of bench work and lead to 
extensive washout of samples. Thus, ATAC-Seq is a 
user-friendly method enabling high-throughput open 
chromatin readout without major sample loss. The 
emergence of combinatorial cellular indexing methods 
enabled to perform ATAC-Seq at a single-cell level; 
for this, DNA barcoding of individual cells is required 
before ATAC-Seq sample preparation [29].
Development of CVDs is frequently accompanied 
by substantial epigenetic changes; for example, human 
atherosclerotic lesions display strong hypomethylation 
of the imprinted chromatin locus 14q32 [30], while 
certain epigenetic programs are activated during 
atrial fibrillation or heart failure [31]. Nonetheless, 
mechanisms of transcriptional regulation remain 
poorly studied. Wide-spread application of ATAC-Seq 
technologies in the field of CVD research will greatly 
advance the understanding of gene expression control 
during disease pathogenesis. 
Conclusion
Emergence of new powerful technologies provide 
an outstanding opportunity for exploration of CVD’s 
pathophysiology at both cellular and molecular levels. 
Approaches reviewed in this paper will undoubtedly 
advance our understanding of CVDs and will uncover 
new horizons in treatment.
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